Edition:
United Kingdom

Becton Dickinson and Co (BDX.N)

BDX.N on New York Stock Exchange

229.36USD
20 May 2019
Change (% chg)

$1.00 (+0.44%)
Prev Close
$228.36
Open
$227.63
Day's High
$230.64
Day's Low
$227.58
Volume
277,974
Avg. Vol
280,628
52-wk High
$265.87
52-wk Low
$208.67

Latest Key Developments (Source: Significant Developments)

Becton Dickinson And Co Reports Q2 Adj EPS Of $2.59
Thursday, 9 May 2019 

May 9 (Reuters) - Becton Dickinson and Co ::BD ANNOUNCES RESULTS FOR 2019 SECOND FISCAL QUARTER; UPDATES FISCAL 2019 GUIDANCE.Q2 ADJUSTED EARNINGS PER SHARE $2.59.Q2 LOSS PER SHARE $0.07.Q2 REVENUE $4.195 BILLION VERSUS REFINITIV IBES ESTIMATE OF $4.24 BILLION.Q2 EARNINGS PER SHARE ESTIMATE $2.58 -- REFINITIV IBES DATA.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $11.65 TO $11.75.SEES FY 2019 REVENUE UP 8 TO 9 PERCENT.REAFFIRMED FULL FISCAL YEAR 2019 COMPARABLE, CURRENCY-NEUTRAL REVENUE GUIDANCE.INCLUDING ESTIMATED ADDITIONAL UNFAVORABLE IMPACT OF FOREIGN CURRENCY, FY ADJUSTED EPS EXPECTED TO GROW ABOUT 6% TO 7%.  Full Article

Bd Receives FDA Approval For Fully Sterile Chlorhexidine Gluconate Antiseptic Skin Preparation
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Becton Dickinson and Co ::BD RECEIVES FDA APPROVAL FOR FULLY STERILE CHLORHEXIDINE GLUCONATE ANTISEPTIC SKIN PREPARATION.BECTON DICKINSON AND CO - FDA APPROVAL FOR BD CHLORAPREP SKIN PREPARATION WITH STERILE SOLUTION.  Full Article

BD Board Declares Dividends
Monday, 29 Apr 2019 

April 29 (Reuters) - Becton Dickinson and Co ::SETS FY DIVIDEND OF $3.08PER SHARE.SETS QUARTERLY DIVIDEND OF $0.77PER SHARE.  Full Article

Retractable Technologies Reports on Fifth Circuit Court's Opinion
Wednesday, 27 Mar 2019 

March 27 (Reuters) - RETRACTABLE TECHNOLOGIES: :RETRACTABLE TECHNOLOGIES - ON MARCH 26, FIFTH CIRCUIT COURT OF APPEALS AFFIRMED DISTRICT COURT'S FINDING ABOUT CO'S CASE AGAINST BECTON, DICKINSON & CO.RETRACTABLE TECHNOLOGIES - EVALUATING FIFTH CIRCUIT RULING & CONFERRING WITH LEGAL COUNSEL REGARDING POSSIBLE FUTURE ACTION.  Full Article

FDA Continues To Recommend Magellan Lead Tests Not Be Used With Samples Taken From Vein
Thursday, 22 Mar 2018 

March 22 (Reuters) - U.S. FDA ::U.S FDA PROVIDES STATEMENT ON FINDINGS FROM ONGOING INVESTIGATION INTO LEAD TESTING ISSUES.U.S. FDA-CONCLUDED THAT STUDIES PERFORMED BY BD WERE ROBUST & SHOWED THERE WAS SIGNIFICANT CHANCE OF FALSE RESULTS WITH MAGELLAN’S LEADCARE TESTS ‍​.U.S FDA SAYS CONTINUES TO RECOMMEND THAT MAGELLAN LEAD TESTS NOT BE USED WITH BLOOD SAMPLES TAKEN FROM THE VEIN.U.S FDA SAYS MAGELLAN’S LEAD TEST SYSTEMS CAN CONTINUE TO BE USED WITH BLOOD SAMPLES FROM A FINGER OR HEEL STICK.AT FDA'S REQUEST, BD IS CONDUCTING TESTING TO DETERMINE IF LAB TESTS OTHER THAN MAGELLAN LEAD TESTS ARE AFFECTED BY THIURAM INTERFERENCE​‍​.  Full Article

Becton, Dickinson To Divest Remaining Investment In Vyaire Medical
Monday, 19 Mar 2018 

March 19 (Reuters) - Becton, Dickinson And Co ::BD TO DIVEST REMAINING INVESTMENT IN VYAIRE MEDICAL TO FUNDS MANAGED BY APAX PARTNERS.‍BD WILL RECEIVE $435 MILLION IN CASH​.‍DIVESTITURE WILL NOT HAVE A MATERIAL IMPACT TO BD REVENUE OR ADJUSTED EARNINGS FOR FISCAL 2018​.‍EXPECTS TO RECORD A GAIN ON TRANSACTION AT TIME OF CLOSING​.‍BD INTENDS TO USE PROCEEDS FROM DEAL IN LINE WITH ITS "BROADER CAPITAL ALLOCATION STRATEGY​".  Full Article

Becton Dickinson Files For Offering EUR 300 Mln Add. 0.368% Notes
Friday, 16 Feb 2018 

Feb 16 (Reuters) - Becton Dickinson And Co ::BECTON DICKINSON AND CO FILES FOR OFFERING EUR 300 MILLION AGGREGATE PRINCIPAL AMOUNT OF ADDITIONAL 0.368% NOTES DUE 2019 - SEC FILING.BECTON DICKINSON AND CO FILES PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED MAY 8, 2017 ‍​.BECTON DICKINSON AND CO SAYS UPON CONSUMMATION OF THE OFFERING, AGGREGATE PRINCIPAL AMOUNT OUTSTANDING OF 0.368% NOTES DUE 2019 WILL BE EUR 1 BILLION.  Full Article

Becton Dickinson Says Received Pre-Market Approval From FDA For BD Onclarity HPV Assay
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - Becton Dickinson And Co ::FDA APPROVES NEW HPV TEST THAT DETECTS AND IDENTIFIES HPV GENOTYPES THAT PUT WOMEN AT HIGH RISK FOR CERVICAL CANCER.  Full Article

Becton Dickinson Q1 Loss Per Share $0.76
Tuesday, 6 Feb 2018 

Feb 6 (Reuters) - Becton Dickinson And Co ::BD ANNOUNCES RESULTS FOR 2018 FIRST FISCAL QUARTER; PROVIDES FISCAL 2018 GUIDANCE UPDATED FOR INCLUSION OF BARD.Q1 LOSS PER SHARE $0.76.Q1 REVENUE $3.08 BILLION.BECTON DICKINSON - EXPECTS FISCAL 2018 ADJUSTED EARNINGS PER SHARE, INCLUDING ACCRETION FROM C.R. BARD ACQUISITION, TO BE BETWEEN $10.85 AND $11.00.BECTON DICKINSON - REAFFIRMS ACQUISITION OF C.R. BARD EXPECTED TO BE ACCRETIVE TO ADJUSTED EARNINGS PER SHARE ON A HIGH-SINGLE DIGIT BASIS IN FISCAL YEAR 2019.BECTON DICKINSON - QTRLY REVENUE INCLUDES ESTIMATED 110 BASIS POINT ADVERSE IMPACT FROM CHANGE IN U.S. DISPENSING BUSINESS MODEL.QTRLY ADJUSTED EARNINGS PER SHARE $2.48.Q1 EARNINGS PER SHARE VIEW $2.41, REVENUE VIEW $3.05 BILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $10.88 -- THOMSON REUTERS I/B/E/S.2018 ‍REVENUES, INCLUDING ACCRETION FROM C.R. BARD DEAL, ARE EXPECTED TO INCREASE ABOUT 30 PERCENT TO 31 PERCENT ON A REPORTED BASIS​.BECTON DICKINSON - ON COMPARABLE, CURRENCY-NEUTRAL BASIS THAT INCLUDES REVS OF C.R. BARD IN CURRENT, PRIOR YEAR, FY 2018 REVENUE EXPECTED TO GROW 4.5-5.5 PERCENT.FY2018 EARNINGS PER SHARE VIEW $10.88, REVENUE VIEW $15.87 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

BD Statement On FDA Warning Letter For Preanalytical Systems Business Unit
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Becton Dickinson And Co ::BD STATEMENT ON FDA WARNING LETTER FOR PREANALYTICAL SYSTEMS BUSINESS UNIT.BECTON DICKINSON - AFTER FDA INSPECTION IN JULY, TOOK ACTION THAT CO BELIEVED FULLY ADDRESSED AGENCY'S INSPECTIONAL OBSERVATIONS.BECTON DICKINSON - "CAREFULLY REVIEWING" FDA'S FEEDBACK OUTLINED IN LETTER WITH HIGHEST SENSE OF URGENCY, TO PROVIDE FULL RESPONSE ON OR BEFORE FEB 1.  Full Article

UPDATE 3-U.S. FDA orders transvaginal surgical mesh pulled from market

April 16 The U.S. Food and Drug Administration on Tuesday ordered makers of transvaginal surgical mesh implants to immediately stop their sale and distribution in the United States, the latest action by the agency to tackle safety issues related to the devices.